Amyotrophic lateral sclerosis: thyroid and prolactin hormone changes in thyrotropin-releasing hormone therapy.
13 patients with amyotrophic lateral sclerosis (ALS) were treated with intravenous infusion of thyrotropin-releasing hormone (TRH). In 6 patients 2 mg/day of TRH was i.v. given over 2 hours for 10 days. In 7 others 2 mg/day of TRH was continuously infused by means of a pump. An increase of thyroid hormones related to the duration of the treatment was observed. A surprising finding was the onset of prolactin (PRL) response to growth hormone releasing hormone (GHRH), previously absent.
Testa
D
D
Divisione di Neurologia, Istituto Nazionale Neurologico C. Besta, Milano.
Chiodini
P G
PG
Girotti
F
F
Attanasio
R
R
D000690:Amyotrophic Lateral Sclerosis / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D013007:Growth Hormone-Releasing Hormone / Q000494:pharmacology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000097:blood* / Q000378:metabolism; D012636:Secretory Rate / Q000187:drug effects; D013268:Stimulation, Chemical; D013973:Thyrotropin-Releasing Hormone / Q000494:pharmacology / Q000627:therapeutic use*; D013974:Thyroxine / Q000097:blood* / Q000378:metabolism; D014284:Triiodothyronine / Q000097:blood* / Q000378:metabolism
D014284:Triiodothyronine; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D013007:Growth Hormone-Releasing Hormone; D013974:Thyroxine